Bingjie Zhou
Sichuan University
Ligand (biochemistry)CancerTargeted drug deliveryIntegrinIn vitroIn vivoProstateChemotherapyInflammationPaclitaxelDrug deliveryDrugProstate cancerTargeted therapyExosomeDoxorubicinCancer researchBreast cancerMedicineDistribution (pharmacology)
Publications 3
#1Bingjie Zhou (Sichuan University)H-Index: 2
#2Min Li (Sichuan University)
Last. Shiqi Huang (Sichuan University)H-Index: 4
view all 13 authors...
Breast cancer was the leading cause of newly diagnosed cases of tumors in 2020, ranking as the second highest cause of female death. Chemotherapy remains the conventional treatment of choice for breast tumors in most clinical cases. However, it is often accompanied by a poor prognosis and severe side effects, resulting from an insufficient accumulation of the drug at tumor sites and an unsystematic distribution of the drug across the body. Inspired by the fact that breast tumor cells overexpress...
#1Luyao Wang (Sichuan University)H-Index: 9
#2Bingjie Zhou (Sichuan University)H-Index: 2
Last. Ling Zhang (Sichuan University)H-Index: 9
view all 11 authors...
Currently, prostate cancer is the most frequently diagnosed cancer in males and chemotherapy is often essential for treating advanced prostate cancer. However, common chemotherapies for prostate cancer suffer from serious adverse effects due to poor drug targeting ability and tissue penetration, even with the help of conventional drug delivery systems. Here, encouraged by recent studies showing possible drug retention and tissue penetration advantages of unconventional non-spherical nanoparticle...
8 CitationsSource
Abstract Currently, most anti-cancer therapies are still haunted by serious and deleterious adverse effects. Here, we report a highly biocompatible tumor cell-targeting delivery systems utilizing exosome-like vesicles (ELVs) that delivers a low-toxicity anti-cancer agent imperialine against non-small cell lung cancer (NSCLC). First, we introduced a novel micelle-aided method to efficiently load imperialine into intact ELVs. Then, integrin α3β1-binding octapeptide cNGQGEQc was modified onto ELV p...
22 CitationsSource